Genome Therapeutics and Genesoft Pharmaceuticals merged with the goal of building a leading integrated biopharmaceutical company committed to delivery of clinical development and marketing of novel anti-infective drugs.
Genome was in the midst of an aggressive transformation from a research-focused to a product-focused company and possessed proven expertise in marketing antibiotics in both the hospital settings and in the community. Genesoft was unique in the biopharmaceutical industry as the only private company with an FDA-approved product ready to be launched in the market. The newly assembled consortium came to Addison Whitney in need of a new corporate identity.
The Addison Whitney Solution
Faced with the challenge to create a new name and logo that represented the company's vision to find the most promising scientific discoveries and bring them to healthcare providers, Addison Whitney recommended the name Oscient Pharmaceuticals. Oscient was chosen to communicate a vision for science while reflecting the company's focus on pharmaceutical development and commercialization of new therapeutics.
The logo designed for Oscient was intended to evoke a patient friendly impression while at the same time expressing the company's involvement with cutting edge technological advances. The image is contoured while portraying a contemporary and progressive organization.